Literature DB >> 28226199

Mortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (≤15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data.

K Atiemo1, A Skaro2, H Maddur1,3, L Zhao1,4, S Montag1,4, L VanWagner1,3,4, S Goel5, A Kho5, B Ho1, R Kang1,6, J L Holl1,6,7, M M Abecassis1, J Levitsky1,3, D P Ladner1,6.   

Abstract

Although the Model for End-Stage Liver Disease sodium (MELD Na) score is now used for liver transplant allocation in the United States, mortality prediction may be underestimated by the score. Using aggregated electronic health record data from 7834 adult patients with cirrhosis, we determined whether the cause of cirrhosis or cirrhosis complications was associated with an increased risk of death among patients with a MELD Na score ≤15 and whether patients with the greatest risk of death could benefit from liver transplantation (LT). Over median follow-up of 2.3 years, 3715 patients had a maximum MELD Na score ≤15. Overall, 3.4% were waitlisted for LT. Severe hypoalbuminemia, hepatorenal syndrome, and hepatic hydrothorax conferred the greatest risk of death independent of MELD Na score with 1-year predicted mortality >14%. Approximately 10% possessed these risk factors. Of these high-risk patients, only 4% were waitlisted for LT, despite no difference in nonliver comorbidities between waitlisted patients and those not listed. In addition, risk factors for death among waitlisted patients were the same as those for patients not waitlisted, although the effect of malnutrition was significantly greater for waitlisted patients (hazard ratio 8.65 [95% CI 2.57-29.11] vs. 1.47 [95% CI 1.08-1.98]). Using the MELD Na score for allocation may continue to limit access to LT.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  cirrhosis; classification systems: Model for EndStage Liver Disease (MELD); clinical research/practice; health services and outcomes research; liver transplantation/hepatology; patient characteristics; patient survival

Mesh:

Substances:

Year:  2017        PMID: 28226199      PMCID: PMC5769449          DOI: 10.1111/ajt.14239

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  26 in total

1.  Bias and causal associations in observational research.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

2.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Authors:  Douglas M Heuman; Souheil G Abou-Assi; Adil Habib; Leslie M Williams; R Todd Stravitz; Arun J Sanyal; Robert A Fisher; Anastasios A Mihas
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

3.  Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications.

Authors:  Teh-Ia Huo; Han-Chieh Lin; Jaw-Ching Wu; Ming-Chih Hou; Fa-Yauh Lee; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  Clin Transplant       Date:  2006 Mar-Apr       Impact factor: 2.863

4.  Nutritional and Functional Status in Geriatric Day Hospital Patients - MNA Short Form Versus Full MNA.

Authors:  E Schrader; E Grosch; T Bertsch; C C Sieber; D Volkert
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

5.  Addressing geographic disparities in liver transplantation through redistricting.

Authors:  S E Gentry; A B Massie; S W Cheek; K L Lentine; E H Chow; C E Wickliffe; N Dzebashvili; P R Salvalaggio; M A Schnitzler; D A Axelrod; D L Segev
Journal:  Am J Transplant       Date:  2013-07-09       Impact factor: 8.086

6.  Current Status of Liver Allocation in the United States.

Authors:  Saleh Elwir; John Lake
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-03

Review 7.  Big data in organ transplantation: registries and administrative claims.

Authors:  A B Massie; L M Kucirka; L M Kuricka; D L Segev
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

Review 8.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

9.  Waitlist Outcomes of Liver Transplant Candidates Who Were Reprioritized Under Share 35.

Authors:  E K H Chow; A B Massie; X Luo; C E Wickliffe; S E Gentry; A M Cameron; D L Segev
Journal:  Am J Transplant       Date:  2016-08-24       Impact factor: 8.086

10.  Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database.

Authors:  David S Goldberg; James D Lewis; Scott D Halpern; Mark G Weiner; Vincent Lo Re
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-11-04       Impact factor: 2.890

View more
  11 in total

1.  Liver-related mortality is similar among men and women with cirrhosis.

Authors:  Nikhilesh R Mazumder; Stela Celaj; Kofi Atiemo; Amna Daud; Kathryn L Jackson; Abel Kho; Josh Levitsky; Daniela P Ladner
Journal:  J Hepatol       Date:  2020-04-25       Impact factor: 25.083

2.  The Hispanic Paradox in Patients With Liver Cirrhosis: Current Evidence From a Large Regional Retrospective Cohort Study.

Authors:  Kofi Atiemo; Nikhilesh R Mazumder; Juan C Caicedo; Daniel Ganger; Elisa Gordon; Samantha Montag; Haripriya Maddur; Lisa B VanWagner; Satyender Goel; Abel Kho; Michael Abecassis; Lihui Zhao; Daniela Ladner
Journal:  Transplantation       Date:  2019-12       Impact factor: 4.939

3.  Living donor liver transplantation versus donation after brain death and donation after circulatory death liver transplantation in the US.

Authors:  Matthew Black; Amar Gupta; Sumeet K Asrani; Tsung-Wei Ma; Giuliano Testa; Anji Wall
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-03-09

4.  The Patient-Centered Outcomes Research Network Antibiotics and Childhood Growth Study: Implementing Patient Data Linkage.

Authors:  Melanie Canterberry; Alan F Kaul; Satyender Goel; Pi-I Debby Lin; Jason P Block; Vinit P Nair; Qianli Ma; Thomas W Carton
Journal:  Popul Health Manag       Date:  2019-12-17       Impact factor: 2.459

Review 5.  A Comprehensive Review of Outcome Predictors in Low MELD Patients.

Authors:  Nikhilesh R Mazumder; Kofi Atiemo; Matthew Kappus; Giuseppe Cullaro; Matthew E Harinstein; Daniela Ladner; Elizabeth Verna; Jennifer Lai; Josh Levitsky
Journal:  Transplantation       Date:  2020-02       Impact factor: 5.385

6.  Accurate long-term prediction of death for patients with cirrhosis.

Authors:  David Goldberg; Alejandro Mantero; David Kaplan; Cindy Delgado; Binu John; Nadine Nuchovich; Ezekiel Emanuel; Peter P Reese
Journal:  Hepatology       Date:  2022-04-01       Impact factor: 17.298

7.  The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.

Authors:  Georg P Györi; David Pereyra; Benedikt Rumpf; Hubert Hackl; Christoph Köditz; Gregor Ortmayr; Thomas Reiberger; Michael Trauner; Gabriela A Berlakovich; Patrick Starlinger
Journal:  Hepatology       Date:  2020-04-23       Impact factor: 17.425

Review 8.  Malnutrition in Patients with Liver Cirrhosis.

Authors:  Julia Traub; Lisa Reiss; Benard Aliwa; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-02-07       Impact factor: 5.717

9.  Frailty and the Burden of Concurrent and Incident Disability in Patients With Cirrhosis: A Prospective Cohort Study.

Authors:  Jennifer C Lai; Jennifer L Dodge; Charles E McCulloch; Kenneth E Covinsky; Jonathan P Singer
Journal:  Hepatol Commun       Date:  2019-10-31

10.  Pre and post-liver transplant outcome of cirrhotic patients with acute on chronic liver failure.

Authors:  Speranta Iacob; Mihaela Ghioca; Irma Eva Csiki; Dana Tomescu; Gabriela Droc; Doina Hrehoret; Vlad Brasoveanu; Corina Pietrareanu; Razvan Iacob; Cristian Gheorghe; Irinel Popescu; Liana Gheorghe
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.